文献速递心脑血管急症呼吸衰竭与机械通气

睡眠呼吸暂停与卒中:叙述性综述

Sleep Apnea and Stroke: A Narrative Review.
PubMed 文献 · Chest · 2024-05-28
一句话结论卒中后OSA常见且与不良预后相关,CPAP可改善认知与神经功能恢复,但对再发卒中和死亡风险无显著获益。

本文为叙述性综述,总结卒中后阻塞性睡眠呼吸暂停(OSA)的流行病学、诊断与治疗证据。OSA是卒中的独立危险因素,卒中后OSA患病率高,与心源性栓塞性卒中和脑小血管病等亚型相关;观察性研究显示未治疗的卒中后OSA与再发卒中、死亡、功能恢复差和住院时间延长相关。客观睡眠监测(家庭睡眠监测或实验室多导睡眠图)推荐用于诊断OSA,CPAP是治疗金标准;随机对照试验显示CPAP改善认知和神经功能恢复等非血管结局,但对再发卒中和死亡风险的随机对照试验结果多为阴性。作者认为需要高质量随机对照试验,通过探索未试验过的治疗策略、按内型和表型个体化干预、选择高危人群及使用反映OSA心血管危害生理异常的指标来验证CPAP等治疗的价值。

要点

  • OSA是卒中的独立危险因素,卒中后OSA患病率高,与心源性栓塞性卒中和脑小血管病等亚型密切相关。
  • 观察性研究显示未治疗的卒中后OSA与再发卒中、死亡、功能恢复差和住院时间延长相关。
  • 推荐使用家庭睡眠监测或实验室多导睡眠图等客观检测诊断OSA;CPAP是治疗OSA的金标准。
  • 随机对照试验显示CPAP改善卒中后OSA患者的认知和神经功能恢复等非血管结局,但对再发卒中和死亡风险的研究结果多为阴性。
  • 作者认为需要高质量随机对照试验,按卒中后OSA内型和表型个体化干预、选择高危人群,以验证CPAP等治疗对减少血管事件和死亡的作用。

适用人群与场景

  • 卒中后阻塞性睡眠呼吸暂停(OSA)患者,包括心源性栓塞性卒中和脑小血管病等卒中亚型。

处置流程与药物剂量

  • 推荐使用家庭睡眠监测或实验室多导睡眠图等客观检测诊断OSA。
  • CPAP是治疗OSA的金标准。

研究设计与关键结果

  • 卒中后OSA患病率高,与多种卒中亚型(包括心源性栓塞性卒中和脑小血管病)密切相关。
  • 观察性研究显示,未治疗的卒中后OSA与再发卒中风险增加、死亡、功能恢复较差和住院时间延长相关。
  • 随机对照试验显示,使用CPAP治疗卒中后OSA可改善认知和神经功能恢复等非血管结局。
  • 评估CPAP对再发卒中风险和死亡影响的随机对照试验结果多为阴性。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对卒中后OSA患者,推荐使用家庭睡眠监测或实验室多导睡眠图进行客观诊断。
  • CPAP是卒中后OSA的治疗金标准,可改善认知和神经功能恢复等非血管结局。
  • CPAP对再发卒中和死亡风险的随机对照试验结果多为阴性,作者认为需要高质量随机对照试验进一步验证CPAP(和/或其他治疗方式)在减少再发血管事件和死亡方面的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

TOPIC IMPORTANCE: Stroke is the second-leading cause of death worldwide. OSA is an independent risk factor for stroke and is associated with multiple vascular risk factors. Poststroke OSA is prevalent and closely linked with various stroke subtypes, including cardioembolic stroke and cerebral small vessel disease. Observational studies have shown that untreated poststroke OSA is associated with an increased risk of recurrent stroke, mortality, poorer functional recovery, and longer hospitalizations.

REVIEW FINDINGS: Poststroke OSA tends to be underdiagnosed and undertreated, possibly because patients with stroke and OSA present atypically compared with the general population with OSA. Objective testing, such as the use of ambulatory sleep testing or in-laboratory polysomnography, is recommended for diagnosing OSA. The gold standard for treating OSA is CPAP therapy. Randomized controlled trials have shown that treatment of poststroke OSA using CPAP improves nonvascular outcomes such as cognition and neurologic recovery. However, findings from randomized controlled trials that have evaluated the effect of CPAP on recurrent stroke risk and mortality have been largely negative.

SUMMARY: There is a need for high-quality randomized controlled trials in poststroke OSA that may provide evidence to support the utility of CPAP (and/or other treatment modalities) in reducing recurrent vascular events and mortality. This goal may be achieved by examining treatment strategies that have yet to be trialed in poststroke OSA, tailoring interventions according to poststroke OSA endotypes and phenotypes, selecting high-risk populations, and using metrics that reflect the physiologic abnormalities that underlie the harmful effects of OSA on cardiovascular outcomes.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Dharmakulaseelan L, Boulos MI. Sleep Apnea and Stroke: A Narrative Review. Chest. 2024. PMID: 38815623. doi:10.1016/j.chest.2024.04.028

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。